Supernus Pharmaceuticals, Inc. (SUPN)

Market Cap	1.79B
Revenue (ttm)	661.82M
Net Income (ttm)	73.87M
Shares Out	55.81M
EPS (ttm)	1.32
PE Ratio	24.23
Forward PE	15.66
Dividend	n/a
Ex-Dividend Date	n/a

Volume	717,641
Open	31.55
Previous Close	31.65
Day's Range	31.37 - 32.02
52-Week Range	25.53 - 40.28
Beta	0.84
Analysts	Hold
Price Target	36.00 (+12.54%)
Earnings Date	Feb 25, 2025

About SUPN

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company’s commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: May 1, 2012
• Employees: 652
• Stock Exchange: NASDAQ
• Ticker Symbol: SUPN
• Website: https://www.supernus.com

Financial Performance

In 2024, Supernus Pharmaceuticals's revenue was $661.82 million, an increase of 8.94% compared to the previous year's $607.52 million. Earnings were $73.87 million, an increase of 5512.84%.

Analyst Forecast

According to 2 analysts, the average rating for SUPN stock is "Hold." The 12-month stock price forecast is $36.0, which is an increase of 12.54% from the latest price.

Price Target

$36.0

(12.54% upside)

Analyst Consensus: Hold